The procedures for holding the Combined General Meeting have been adapted in accordance with Article 4 of Ordinance No. 2020-321 of
In accordance with Article 4 of Covid-19 Ordinance, the AGM must be held without the shareholders and other persons entitled to attend being physically present. Shareholders are therefore invited to vote at the general meeting either by mail or by proxy.
The Notice of Meeting of this AGM was published on
All documentation regarding this AGM will be published on the Company’s website as of today.
Precision regarding the AGM:
Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight
Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post.
Written questions from shareholders must be received from the day of the publication of the official convocation to the AGM up until four business days prior to the AGM (by e-mail to investors@innate-pharma.com).
Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French Code de Commerce) by sending a request by e-mail to investors@innate-pharma.com.
About
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and
Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Based in
Learn more about
Information about
ISIN code Ticker code LEI | FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer:
Neither this press release nor the information contained herein constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in
For additional information, please contact:
Investors Innate Pharma Tel.: +1 917 499 6240 Danielle.Spangler@innate-pharma.com Tel.: +33 (0)4 30 30 30 30 investors@innate-pharma.com | Media Innate Pharma Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.com Marie Puvieux ( Tel.: +33 (0)9 81 87 46 72 innate-pharma@atcg-partners.com |
Source:
2020 GlobeNewswire, Inc., source